Ortho Clinical Diagnostics today announced that it has received CE mark for Ortho's VITROS® XT 7600 Integrated System. By combining Ortho's proprietary dry slide technology with sophisticated digital imaging capabilities and the potential to perform two separate lab tests simultaneously, Ortho is introducing digital chemistry to clinical lab management. Digital chemistry brings powerful data intelligence, operational improvements and heightened quality to the lab to help clinical laboratories keep pace with a rapidly evolving global health care environment, without requiring additional lab space.
"Ortho's VITROS® XT 7600 harnesses the power of our proprietary dry slide technology to deliver even more enhanced, high-quality test results, higher throughput and an improved patient experience, all within the lab's existing physical footprint," said Robert Yates, chief operating officer of Ortho Clinical Diagnostics. "It's a fundamental change to the way labs operate."
The digital chemistry behind Ortho's VITROS® XT 7600 is based on three enabling technologies:
Dry slide technology. Unlike traditional wet chemistry systems, which require highly purified water and complex plumbing systems to operate, Ortho's proprietary dry slide technology does not require water to run. This eliminates the risk that poor water quality could impact test results.
MicroSlide. A full testing environment on a postage-stamp-sized piece of film enables precise and accurate testing in a waterless environment.
Digital imaging technology. Advanced optics glean significantly more information from testing than has been possible to date, enabling better precision and powerful data intelligence functions in the lab.
In addition, Ortho's VITROS® XT 7600 increases productivity, with less patient blood sample required, by introducing multi-test processing – the potential to offer two tests per slide instead of one -- to clinical chemistry. With XT MicroSlides1, the instrument will provide the ability to pair tests that are frequently ordered for the same patient so they can be run simultaneously. This saves time and space in the lab, and reduces the amount of blood needed for testing, an important advantage for vulnerable patients or those with venous access issues.
"We are an internationally renowned laboratory where quality comes first. The Ortho technology is stable and filters out most common interferences to deliver a high first-pass yield and minimal reruns," said Phil Craddock-Jones, lab manager, Sheffield Children's Hospital in the UK. "Ortho's VITROS® Systems don't require water to run, which reduces the risk of water contamination."
The Ortho VITROS® XT 7600 Integrated System has received CE Mark signifying conformance to applicable European Union regulationory requirements and is now available for purchase in numerous countries in Europe, the Middle East, Africa, Asia and Latin America.
SOURCE Ortho Clinical Diagnostics
Related Links
http://www.orthoclinicaldiagnostics.com
No comments:
Post a Comment